Antibodies Market will cross a valuation of US$ 3,000 Mn by 2022-end

Fact.MR has published a research report on global Antibodies market assessing the period between 2017 to 2022. Antibodies (Ab) are also known as immunoglobulin (Ig). These are the large, Y-shaped protein that are produced primarily by plasma cells present in the blood in response to pathogens such as viruses and bacteria. Antibodies are capable of identifying unique molecules with harmful agents. Antibodies are used in various therapeutic areas as well as in diagnostics of disease indications such as rheumatoid arthritis, non-Hodgkin lymphoma, psoriasis, macular degeneration, asthma, Crohn’s disease, and hypercholesterolemia.

Explore how Europe region is performing for Antibodies Market:  https://www.factmr.com/connectus/sample?flag=S&rep_id=194

Outbreak of COVID-19 to Provide Impetus to Market Growth

The overall competitive landscape of the global antibodies market is a quite fragmented in nature. The companies in the market are focusing on aggressive growth strategies such as mergers, takeovers, and acquisition in order to stay ahead of the competition. Moreover, the companies in the market are collaborating with notable research institutes and establishments to develop cure for prolonged viral diseases. Case in point – COVID-19 vaccine. Several companies operating in the market such as Abcam Plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Genscript Biotech Corporation, Sigma Aldrich Corp, Crown Bioscience, Inc., Thermo Fisher Scientific, Inc. have started working on the development of COVID-19 antibodies. The market is expected to witness a tough competition in the coming years of the forecast period ranging from 2017 to 2022. Currently, the vaccine developed by AstraZeneca and Pfizer have received emergency approval for distribution. Such developments are likely to fuel the development of the global market in the near future.

Explore Fact.MR's lucid coverage of the Healthcare landscape

There are multiple factors that are expected to help the overall development of the global antibodies market. One of the driving factor for the market has been the prevalence of chronic ailments and disorders across the globe. With multiple diseases such as different types of cancer, chronic heart disorders, diabetes, and frequent outbreak of infectious diseases, there are several growth opportunities for the global antibodies market. With such prominent factors driving the market growth, the Global antibodies is expected to reach a valuation worth US$1,091 Mn by the end of the forecast period ranging from 2017 to 2022. The primary antibodies segment is projected to create an absolute growth opportunity of US$ 168.4 Mn between 2017 and 2022.

Get Customization on this Research Report for specific research solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=194

North America to Continue Dominate Global Market

In terms of regional segmentation, there are five key regions of the global antibodies market. These are North America, Latin America, Middle East and Africa, Europe, and Asia Pacific. Currently, North America dominates the global antibodies market in terms of revenue and trend is projected continue in 2017 and beyond. In addition, the market in the region is expected to increase at a moderate CAGR during the forecast period (2017-2022). Presence of leading market players and existence of a well-established healthcare infrastructure is supporting the growth of the market in the region.

Explore Fact.MR's Comprehensive Coverage on Healthcare Landscape

Rheumatoid Arthritis Stem Cell Therapy Market- On the back of the increasing popularity across specialty clinics, ambulatory surgical centers, and, hospitals, a recent study by Fact.MR foretells that, the rheumatoid arthritis stem cell therapy market would record a value around to US$ 12 Bn towards 2027 end.

Epidermal Cell sheets Market - Restricted lifespan of the products, higher cost associated with the product procedure, and risk related to the epidermal cell sheets are the key obstacle to the market expansion of epidermal cell sheets.